Skip to main content
. Author manuscript; available in PMC: 2008 Apr 7.
Published in final edited form as: Behav Neurosci. 2004 Aug;118(4):715–729. doi: 10.1037/0735-7044.118.4.715

Table 2.

Results of Statistical Analyses for Experiment 1, Session 13 (Phase 4; AP-5 in CeA)

Source of variation df F p
Previous drug history 1, 10 1.440 .258
Current drug state 1, 10 35.830 < .001
Previous × Current 1, 10 0.859 .376

Note. AP-5 = 2-amino-5 phosphonopentanoic acid; CeA = central nucleus of the amygdala. Boldface indicates a significant effect of AP-5.